These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 16294264

  • 1. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE.
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB, Geusens P, Barton IP, Felsenberg D.
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [Abstract] [Full Text] [Related]

  • 7. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P.
    Menopause; 2008 Apr; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [Abstract] [Full Text] [Related]

  • 9. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S.
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 11. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 12. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR.
    J Bone Miner Res; 2007 Apr; 22(4):503-8. PubMed ID: 17243862
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [Abstract] [Full Text] [Related]

  • 14. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Jan; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 15. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
    Yanik B, Bavbek N, Yanik T, Inegöl I, Kanbay M, Turgut FH, Uz E, Akçay A.
    Ren Fail; 2007 Jan; 29(4):471-6. PubMed ID: 17497471
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.